EUVIMEDEUVIMED entdecken
Open Access

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening

Dana H Chung, Tanner J Caverly, Matthew J Schipper, Timothy P Hofer, Roman Gulati, Brent S Rose, Megan E V Caram, Phoebe A Tsao, Kristian D Stensland, David Elliott, Sameer D Saini, Alex K Bryant

JAMA Network Open · 14.02.2025 · 8 (2) · e2459766

DOI: 10.1001/jamanetworkopen.2024.59766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 14.02.2025. Verfasst von Dana H Chung und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Early Detection of Cancer. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Continuing prostate-specific antigen (PSA) screening after age 70 years might benefit men at high risk of prostate cancer–specific mortality (PCSM) or metastatic prostate cancer (mPCa), but the relative value of clinical factors (race and ethnicity, competing mortality, and PSA history) in identifying men at higher vs lower risk is unknown.

Objective

To examine the value of PSA levels, race and ethnicity, and competing mortality in risk stratification for PCSM and mPCa in men after age 70 years. Design, Setting, and Participants In this cohort study, clinical data of all men receiving health care through the Veterans Health Administration who turned age 70 years between 2008 and 2020 and had a normal screening PSA value between age 65 and 69 years (<4 ng/mL [baseline PSA]) and no prior history of prostate cancer or biopsy were examined. The data cutoff date was December 26, 2023. Exposure The most recent screening PSA value from age 65 to 69 years, self-reported race and ethnicity, and competing mortality risk derived from a machine learning model. Main Outcome and Measures The 10-year absolute risk of PCSM and mPCa were determined using regression modeling.

Results

The cohort included 921 609 men who turned 70 years between 2008 and 2020; 11% of whom self-reported as Black and 82% as White race. Between age 65 and 70 years, 45% of patients had a baseline PSA of less than 1.00 ng/mL, and 32% had a baseline PSA of 1.00 to 1.99 ng/mL. Most patients (87%) continued to undergo screening past age 70 years, with little variation by competing mortality risk or race and ethnicity. The 10-year cumulative incidence of PCSM was 0.26% overall, and 95% of men had a 10-year risk less than 0.73%. Higher baseline PSA level between age 65 and 69 years was associated with 10-year PCSM risk (0.79% for 3.00-3.99 ng/mL vs 0.10% for 0.20-0.99 ng/mL), race and ethnicity (0.36% for Black vs 0.25% for White), and competing mortality (0.24% for the highest quintile vs 0.21% for the lowest quintile). Similar results were found for mPCa. Low PSA (0.20-0.99 ng/mL) was associated with very low PCSM and mPCa risk, even among Black men in the healthiest quintile of competing mortality risk (10-year PCSM risk, 0.08% [95% CI, 0.01%-0.44%]; 10-year mPCa risk 0.24% [95% CI, 0.10%-0.52%]). Conclusions and Relevance In this cohort study, the findings suggest that most men receiving care through the VHA continue PSA screening after age 70 years despite low absolute 10-year PCSM risks. The PSA values from age 65 to 69 years may be highly informative for adverse prostate cancer outcomes after age 70 years, with a PSA less than 1 ng/mL associated with a very low risk of long-term PCSM and mPCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenEarly Detection of CancerHumansMaleAgedUnited StatesCohort StudiesRisk AssessmentMass Screening

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • University of Michigan Medical School, Ann Arbor.
  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
  • Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Biostatistics, University of Michigan, Ann Arbor.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.

Förderung

  • NCI NIH HHS

Zitieren

APA

Chung, D. H., Caverly, T. J., Schipper, M. J., Hofer, T. P., Gulati, R., Rose, B. S., Caram, M. E. V., Tsao, P. A., Stensland, K. D., Elliott, D., Saini, S. D., & Bryant, A. K. (2025). Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening. JAMA Network Open, 8(2), e2459766. https://doi.org/10.1001/jamanetworkopen.2024.59766

Vancouver

Chung DH, Caverly TJ, Schipper MJ, Hofer TP, Gulati R, Rose BS, et al. Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening. JAMA Network Open. 2025;8(2):e2459766. doi:10.1001/jamanetworkopen.2024.59766

BibTeX
@article{Chung2025,
  author = {Chung, Dana H and Caverly, Tanner J and Schipper, Matthew J and Hofer, Timothy P and Gulati, Roman and Rose, Brent S and Caram, Megan E V and Tsao, Phoebe A and Stensland, Kristian D and Elliott, David and Saini, Sameer D and Bryant, Alex K},
  title = {Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {e2459766},
  doi = {10.1001/jamanetworkopen.2024.59766}
}
Kostenlos starten →